S&P 500   3,850.78
DOW   31,169.48
QQQ   323.47
S&P 500   3,850.78
DOW   31,169.48
QQQ   323.47
S&P 500   3,850.78
DOW   31,169.48
QQQ   323.47
S&P 500   3,850.78
DOW   31,169.48
QQQ   323.47
Log in

Indonesia green-lights emergency use of Chinese vaccine

Monday, January 11, 2021 | Victoria Milko And Edna Tarigan, Associated Press


A health worker gives an injection to a mock patient during a coronavirus vaccine drill in Bali, Indonesia on Monday, Jan. 11, 2021. Indonesia's highest Islamic body has gave its religious approval to China's Sinovac vaccine, paving the way for its distribution in the world's most populous Muslim nation. (AP Photo/Firdia Lisnawati)

JAKARTA, Indonesia (AP) — Indonesia’s Food and Drug Authority on Monday green-lighted emergency use of the COVID-19 vaccine produced by China-based Sinovac Biotech Ltd., with vaccinations of high-risk groups expected to start later this week.

Conditional vaccination of healthcare workers and other civil servants using the vaccine, called CoronaVac, is expected to begin this week.

“Based on the data and considering the guidance from (the World Health Organization), CoronaVac has met the requirements to get the permit to use the vaccine,” the chief of Indonesia Food and Drug Monitoring Agency, Penny Lukito, said at a news conference.

Indonesian President Joko Widodo said he would be the first person to receive the vaccine.

“Why is the President first? It’s not about putting myself first, but to ensure everyone that this vaccine is safe and halal,” Widodo said on social media.

The vaccine was cleared for emergency use after Indonesian authorities reviewed clinical trial data from Brazil, Turkey and Indonesia, which are all taking part in Phase III clinical trials of the vaccine.

Brazil’s Instituto Butantan said last week that the vaccine was 78% effective in mild cases and 100% effective against severe and moderate infections based on 220 COVID-19 cases from 13,000 volunteers.

In December, Turkish authorities announced an efficacy rate of 91.25% from interim analysis of 29 cases in a trial with 7,371 volunteers. Some 12,450 volunteers, including 1,500 healthcare workers, are involved in the Phase III clinical trials. Further results have not been made publicly available.

Indonesia conducted its own Phase III clinical trials of the vaccine with 1,620 volunteers. Results announced at Monday's news conference said the efficacy rate was 65.3%.

Indonesia's highest Islamic body, the Indonesian Ulema Council, announced last week that the COVID-19 vaccine is halal, or fit for consumption by Muslims, further paving the way for use and distribution in the world's most populous Muslim country.

But some experts have said they would prefer more data from the clinical trials.

Griffith University epidemiologist Dr. Dicky Budiman said that many people have questioned and expressed doubt about the vaccine, as the data Indonesia used for emergency authorization is only preliminary.

Research into the vaccine is not completed yet and will still take some time, he said.

Sao Paulo’s Butantan Institute, Sinovac Biotech Ltd.’s partner in Brazil, did not disclose data such as results by age and gender or the number of asymptomatic volunteers in the sample, which many epidemiologists require to assess whether the shot complies with safety standards. Officials in Brazil said details would be published after Brazil’s health regulatory agency approves the vaccine.

Authorities in China and Bolivia have both issued emergency authorization for the CoronaVac vaccine. Chinese health officials have said that some 9 million doses have been administered in China, though the number of people being vaccinated with the Sinovac vaccine has not been disclosed. Bolivia has yet to start vaccinations with the CoronaVac vaccine.

Several other countries that were not involved in clinical trials have signed agreements or are in negotiations to secure doses from Sinovac Biotech Ltd., including the Philippines, Singapore, Ukraine, Bolivia and others.

Indonesia has recorded more than 828,000 cases of the virus, including over 24,000 deaths.

___

Associated Press writers Huizhong Wu in Taipei, Taiwan, and Suzan Fraser in Ankara, Turkey, contributed to this report.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Sinovac Biotech (SVA)0.5$6.47flatN/A35.94N/AN/A
Compare These Stocks  Add These Stocks to My Watchlist 


12 Marijuana Stocks to Buy Now

There are now more than 50 publicly-traded companies operating in the cannabis industry. Most of these companies aren't directly growing and selling marijuana themselves, but they do stand to benefit greatly as more states legalize the sale and possession of marijuana. Some of these marijuana stocks are media companies. Others are privately studying the medical uses of marijuana. Yet others are providing tools and software for marijuana growers. As more cannabis companies file IPOs and enter the stock market, it will become increasingly difficult for investors to identify which marijuana stocks will truly benefit from the cannabis boom.

Our subscribers have begun digging through these companies, checking out their financials, business models and long-term growth prospects. They know that some "marijuana stocks" are just empty shell companies that deserve to be penny stocks, but they also recognize there are some legitimate and growing companies that truly stand to benefit from the green rush. As a group, they have added 10 different cannabis stocks to their watchlists and are actively investing in them. More than 1,400 MarketBeat subscribers are now following our top-trending cannabis company.

This slide show lists the 12 pot stocks that MarketBeat subscribers are have added to their watchlists and are actively monitoring.

View the "12 Marijuana Stocks to Buy Now".

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.